29 results
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
green staining in the images at both 50 and 150 mg/kg treatment (Fig. 3). Thus, functional reversal in the gut is accompanied by clearance of toxic … (Rabbit Polyclonal; Green) and VaCht (Goat polyclonal; Red) and with appropriate secondary antibodies. The tissues were then mounted with Prolong Anti
POS AM
mjz6l8nh
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
PRE 14A
1leptwn763pa79vkw
21 Apr 22
Preliminary proxy
4:33pm
8-K
EX-99.1
vuz9z
21 Apr 22
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
p21x ul20sa
24 Mar 22
Regulation FD Disclosure
9:17am
8-K
EX-99.1
e6b9bvgzqdh
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
8-K
EX-99.1
c0ms7s3 sgrhagleb0
19 Oct 21
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT
5:03pm
8-K
EX-99.1
g01yv0ub
17 Aug 21
Regulation FD Disclosure
5:02pm
424B4
bo6q3v7
17 Jun 21
Prospectus supplement with pricing info
4:31pm
DRS
77an5lfo
2 Jun 21
Draft registration statement
12:00am
8-K
EX-99.1
bcs6y1mq s59xm
1 Jun 21
Regulation FD Disclosure
7:30am
DEFA14A
8wjmzrlgt 88kko
30 Apr 21
Additional proxy soliciting materials
5:21pm
DEF 14A
6a8dk
30 Apr 21
Definitive proxy
5:20pm